<SUBMISSION>
<ACCESSION-NUMBER>0001144204-10-033069
<TYPE>DEFA14A
<PUBLIC-DOCUMENT-COUNT>3
<FILING-DATE>20100611
<DATE-OF-FILING-DATE-CHANGE>20100611
<EFFECTIVENESS-DATE>20100611
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>Neuralstem, Inc.
<CIK>0001357459
<ASSIGNED-SIC>2836
<IRS-NUMBER>522007292
<STATE-OF-INCORPORATION>DE
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>DEFA14A
<ACT>34
<FILE-NUMBER>001-33672
<FILM-NUMBER>10892465
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>9700 GREAT SENECA HIGHWAY
<CITY>ROCKVILLE
<STATE>MD
<ZIP>20850
<PHONE>3013664841
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>9700 GREAT SENECA HIGHWAY
<CITY>ROCKVILLE
<STATE>MD
<ZIP>20850
</MAIL-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>v188074_8k.htm
<TEXT>
<html>
  <head>
    <title></title>
    <!--Licensed to: vf-->
    <!--Document Created using EDGARizer 4.0.6.1-->
    <!--Copyright 1995 - 2008 EDGARfilings, Ltd., an IEC company. All rights reserved-->
    </head>
    <body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
    <div>
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 20pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #000000">SECURITIES AND EXCHANGE
COMMISSION</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #000000">WASHINGTON, D.C.
20549</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font>

      <div>
        <hr style="COLOR: black" align="center" noshade size="2" width="15%">
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 20pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #000000">FORM 8-K</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #000000">CURRENT REPORT</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #000000">Pursuant to Section 13 or 15(d) of
the</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #000000">Securities Exchange Act of
1934</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #000000">Date of report (Date of earliest event
reported): June 11, 2010</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <hr style="COLOR: black" align="center" noshade size="2" width="15%">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 20pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #000000">Neuralstem, Inc.</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #000000">(Exact name of registrant as specified
in Charter)</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div align="left">
      <table cellpadding="0" cellspacing="0" width="100%">
          <tr>
            <td valign="top" width="24%" style="BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; COLOR: #000000">Delaware</font></font></div>
            </td>
            <td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="top" width="24%" style="BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; COLOR: #000000">000-1357459</font></font></div>
            </td>
            <td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="top" width="24%" style="BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; COLOR: #000000">52-2007292</font></font></div>
            </td>
          </tr>
          <tr>
            <td valign="top" width="24%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; COLOR: #000000">(State or other jurisdiction
      of</font></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; COLOR: #000000">incorporation or
      organization)</font></font></div>
            </td>
            <td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="top" width="24%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; COLOR: #000000">(Commission File
      No.)</font></font></div>
            </td>
            <td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="top" width="24%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; COLOR: #000000">(IRS Employee Identification
      No.)</font></font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">9700
Great Seneca Highway, Rockville, Maryland 20850</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #000000">(Address of Principal Executive
Offices)</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(301)
366-4841</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #000000">&#160;(Issuer Telephone
number)</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div>
      <hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #000000">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (see General Instruction
A.2. below):</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #000000"><font style="DISPLAY: inline;" face="Wingdings">o</font> Written communications
pursuant to Rule 425 under the Securities Act (17 CFR
230.425)</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #000000"><font style="DISPLAY: inline;" face="Wingdings">x</font> Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #000000"><font style="DISPLAY: inline;" face="Wingdings">o</font> Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #000000"><font style="DISPLAY: inline;" face="Wingdings">o</font> Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td align="right" style="WIDTH: 54pt">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #000000">Item&#160;<font style="DISPLAY: inline; COLOR: #000000">8</font><font style="DISPLAY: inline; COLOR: #000000">.01</font>&#160;</font></font></div>
            </td>
            <td align="left">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #000000">Other Events</font></font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On June
11, 2010, Neuralstem, Inc.&#160;&#160;(the &#8220;Company&#8221;) made available on its
website a letter from management to its shareholders regarding the Company&#8217;s
developments over the past year.&#160;&#160;The Company anticipates this letter
will be mailed to shareholders along with the Company&#8217;s Proxy Statement and
Annual Report in connection with the 2010 Annual Meeting of
Shareholders.&#160;&#160;A copy of the letter is attached to this Form 8-K as
Exhibit 99.01 and is incorporated herein by reference.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
information contained in this Current Report on Form 8-K and the exhibits
attached hereto shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of
the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or
otherwise subject to the liabilities of that section, nor shall such information
or such exhibits be deemed incorporated by reference in any filing under the
Securities Act of 1933, as amended, or the Exchange Act, except as shall be
expressly set forth by specific reference in such a filing. The information set
forth in or exhibits to this Form 8-K shall not be deemed an admission as to the
materiality of any information in this report on Form 8-K.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Additional
Information</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
Company plans to mail to its shareholders a proxy statement in connection with
the 2010 Annual Meeting of Shareholders.&#160;&#160;&#160;The Company and its
respective directors and executive officers may be deemed to be participants in
the solicitation of proxies. Information regarding our directors and executive
officers is contained in the Company&#8217;s proxy statement filed with the Securities
and Exchange Commission (&#8220;SEC&#8221;) on June 4, 2010. The proxy statement contains
important information about the Company and related matters, including the
current security holdings of the Company&#8217;s respective officers and
directors.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
written materials described above and other documents filed by the Company with
the SEC will be available free of charge from the SEC&#8217;s website at
www.sec.gov.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
      <table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">
          <tr valign="top">
            <td align="right" style="WIDTH: 54pt">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #000000">Item&#160;9.01&#160;</font></font></div>
            </td>
            <td align="left">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #000000">Financial Statement and
      Exhibits.</font></font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">
          <tr>
            <td align="left" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; COLOR: #000000">Exhibit
    Number</font></font></div>
            </td>
            <td valign="bottom" width="5%" style="PADDING-BOTTOM: 2px">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;</font></div>
            </td>
            <td align="left" valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: times new roman">      </font>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; COLOR: #000000">Description</font></font></div>
            </td>
            <td align="left" valign="bottom" width="8%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: times new roman">      </font>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="left">&#160;</div>
            </td>
            <td align="left" valign="bottom" width="17%" style="PADDING-BOTTOM: 2px">&#160;</td>
            <td align="left" valign="bottom" width="33%" style="PADDING-BOTTOM: 2px">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="left">&#160;</div>
            </td>
          </tr>
          <tr>
            <td valign="middle" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="middle" width="5%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td colspan="4" valign="middle" width="66%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
          </tr>
          <tr>
            <td align="left" valign="top" width="7%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">99.01</font></div>
            </td>
            <td valign="bottom" width="5%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" colspan="4" valign="bottom" width="66%">
              <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Letter
      to Shareholders</font></div>
            </td>
          </tr>
          <tr>
            <td valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="bottom" width="5%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td colspan="4" valign="bottom" width="66%"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #000000">SIGNATURES</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this Report on Form 8-K to be signed on its behalf by the
undersigned hereunto duly authorized.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <div>
        <table border="0" cellpadding="0" cellspacing="0" width="100%">
            <tr>
              <td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
              <td colspan="2" valign="top" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Neuralstem,
      Inc.</font></td>
              <td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
            </tr>
            <tr>
              <td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
              <td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
              <td valign="top" width="35%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
              <td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
            </tr>
            <tr>
              <td align="left" valign="top" width="50%" style="BORDER-BOTTOM: #ffffff solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Date:&#160;&#160;&#160;June
      11, 2010&#160;</font></div>
              </td>
              <td valign="top" width="3%" style="BORDER-BOTTOM: #ffffff solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              </td>
              <td align="left" nowrap valign="bottom" width="35%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">/s/&#160;Richard
      Garr</font></td>
              <td valign="top" width="12%" style="BORDER-BOTTOM: #ffffff solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
            </tr>
            <tr>
              <td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
              <td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
              <td align="left" nowrap valign="bottom" width="35%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">By:&#160;&#160;Richard
      Garr</font></td>
              <td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
            </tr>
            <tr>
              <td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
              <td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
              <td valign="top" width="35%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Chief
      Executive Officer</font></td>
              <td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
            </tr>
        </table>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.01
<SEQUENCE>2
<FILENAME>v188074_ex99-01.htm
<TEXT>
<html>
  <head>
    <title></title>
    <!--Licensed to: vf-->
    <!--Document Created using EDGARizer 4.0.6.1-->
    <!--Copyright 1995 - 2008 EDGARfilings, Ltd., an IEC company. All rights reserved-->
    </head>
    <body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
    <div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exhibit
99.01</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    </div>
    <div style="TEXT-ALIGN: center"><IMG SRC="neuralstemlogo.jpg"></div>
    <div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div>
        <table cellpadding="0" cellspacing="0" width="100%">
            <tr>
              <td valign="top" width="40%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Dear
      Fellow Shareholders,</font></div>
              </td>
              <td valign="top" width="40%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">June
      10, 2010</font></div>
              </td>
            </tr>
        </table>
      </div>
    </div>
    <div>&#160;</div>
    <div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The past
year has been a year of great progress for our company: we strengthened our
balance sheet despite the challenging financial environment; we added to our
Intellectual Property assets with the issuance of two new important patents; and
we launched the world&#8217;s first FDA approved Neural Stem Cell Clinical Trial to
treat Amyotrophic Lateral Sclerosis (ALS), commonly referred to as Lou Gehrig&#8217;s
disease.&#160;&#160;We believe that this coming year will mark even greater
strides forward as we continue the ALS trial, move into a clinical trial to
treat spinal cord injury; move our small molecule drug into the clinic for
hopefully both Alzheimer&#8217;s Disease and Major Depression; and continue to expand
into Asia with the creation of our wholly owned subsidiary Neuralstem China
<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-FAMILY: Times New Roman">&#31070;&#33041;&#29983;&#29289;&#21307;&#33647;&#20844;&#21496;
</font>(Sun-Now Biopharmaceutical Company), as well as pursue strategic
development in India.</font></div>
    </div>
    <div>&#160;</div>
    <div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">First, a
note on our ongoing Phase I clinical trial at Emory University to treat
ALS:&#160;&#160;As we announced on May 24<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">th</font>, 2010,
after reviewing the safety data from the first cohort of 3 patients, the
Independent Data Safety Monitoring Board gave the approval to move to the second
cohort of 3 patients, the first of whom was transplanted on May 26<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">th</font>.&#160;&#160;The
first cohort of 3 patients received only 5 injections each,
unilaterally.&#160;&#160;The second cohort of patients is receiving 10
injections each, bilaterally, in the lower spinal cord.&#160;&#160;Demonstrating
the safety of the increased dosage is a critical element in what we hope will
ultimately be the delivery of our cells through 15 injections for ALS
patients.&#160;&#160;The surgery on the third patient, performed in April, was
the subject of a special feature by Dr. Sanjay Gupta M.D., a neurosurgeon and
CNN&#8217;s chief medical correspondent on Anderson Cooper&#8217;s <font style="DISPLAY: inline; COLOR: #000000">AC360&#176;</font>.&#160;&#160;In addition to
remarkable footage of the actual surgery, the piece contains insights into the
program from the Principal Investigator, Dr. Eva Feldman and the Emory
neurosurgeon conducting the surgeries, Dr. Nick Boulis.&#160;&#160;For those of
you who have not watched it, a link can be found on our website&#160;&#160;<font style="DISPLAY: inline; COLOR: #0000ff; TEXT-DECORATION: underline">www.neuralstem.com</font>;
I highly recommend watching it.</font></div>
    </div>
    <div>&#160;</div>
    <div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Of
additional importance is that we intend to treat both chronic and acute spinal
cord injury with the same spinal cord stem cells utilizing the same injection
devices we are using for ALS.&#160;&#160;The treatment for spinal cord injury
will, however, likely only involve a few injections as opposed to the fifteen
injection dosage that is ultimately planned for the ALS trial. We therefore add
to our knowledge about the surgical route of entry for both the ALS patients and
the spinal cord injury patients with each patient we treat in the ALS
trial.&#160;&#160;We expect to file an Investigational New Drug application with
the FDA this year to begin a Phase I clinical trial for Chronic Spinal Cord
Injury, in what will most likely be a multi-site study in the U.S.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify" align="left">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Another
important milestone for Neuralstem in 2009 was the issuance of a U.S. Patent
entitled &#8220;Use of Fused Nicotinamides to Promote Neurogenesis.&#8221; This patent
claims four chemical entities and any pharmaceutical composition including them.
The compounds promote neurogenesis - the birth of new neurons in the adult
brain. These four molecules with demonstrated neurogenic activity, are
first-in-class compounds, were discovered entirely in-house and are owned 100%
by Neuralstem. These are the only drugs we are aware of with the demonstrated
ability to stimulate neurogenesis of normal adult brain cells, which indicates
that they are truly neurogenic.&#160;&#160;We have been &#8220;incubating&#8221; the
development of this new class of drugs inside the Company.&#160;&#160;The
original development funding of $2.5 million came from the U.S. Department of
Defense, and an additional $250,000 from the National Institutes of
Health.&#160;&#160;The compounds enhance neurogenesis in the hippocampus. There
is now a consensus in the scientific community that neural stem cells exist in
this region of the adult brain.&#160;&#160;Through work done over the past year,
we believe that we have the proof of concept needed to justify entering human
trials with our lead compound from this group. We expect to be ready to begin
the first Phase I trial near the end of 2010 or early in 2011. The two primary
targets for the first trials are Alzheimer&#8217;s disease and Major
Depression.&#160;&#160;The decision has not yet been made as to which will be
the first, or whether in fact we may do both.&#160;&#160;We are committed,
however, to moving the small molecule program into the clinic.&#160;&#160;The
key reason for our expansion into small molecule drugs is that these compounds
were discovered screening against our human hippocampol stem
cells.&#160;&#160;We believe that our ability to screen against our cells
provides a valuable and unique advantage for the discovery of novel compounds
for the treatment of diseases of the Central Nervous System.&#160;&#160;We
believe that this first program will be a powerful validation of our screening
technology.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify" align="left">&#160;</div>
        <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="FTR">
            <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
          </div>
          <div id="PN" style="PAGE-BREAK-AFTER: always">
            <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
              <hr style="COLOR: black" noshade size="2">
            </div>
          </div>
          <div id="HDR">
            <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify" align="left">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Finally,
I would like to say a word about our overseas activities.&#160;&#160;We are
still committed to expanding throughout the world.&#160;&#160;In the first
quarter of 2009, scientists at University Hospital Frieburg, Germany presented
data at the Huntington's Disease Therapeutics Conference in France, entitled,
&#8220;Validation of Human Neural Stem Cell line in Rodent Model of Huntington&#8217;s
Disease,&#8221; which demonstrated robust survival of our spinal cord stem cells,
integration into the host brain, and early graft-mediated functional effect.
This is a major milestone in the process of qualifying our cells into the
hospital&#8217;s existing human trial in Germany to treat Huntington&#8217;s disease with
our cells, as well as supporting our work in the U.S.</font></div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify" align="left">&#160;</div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify" align="left">
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Also, we
have a strong emphasis on expanding into Asia.&#160;&#160;Over the next year we
believe that CJ Cheljedang, who holds an option on the commercialization rights
to our spinal cord cells for South Korea, Vietnam, Singapore, Malaysia and
Indonesia, will most likely chose the site and indication for its first clinical
trial.&#160;&#160;And as mentioned above, we are expecting to commence business
through our wholly owned subsidiary in China this summer.&#160;&#160;&#160;We
believe that China presents tremendous growth opportunity for us both in terms
of accelerated product development as well as prospective markets for our
therapies.</font></div>
          </div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify" align="left">&#160;</div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify" align="left">
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">So as we
head into the second half of 2010, once again we have a full
plate.&#160;&#160;&#160;We look forward to keeping you up to date as we progress
on all these fronts.</font></div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Sincerely,
</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Karl
JoheChairman of the Board &amp; Chief Scientific Officer</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">I.
Richard Garr</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Director,
President &amp; Chief Executive Officer</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">The
statements and certain other information contained in this letter, which can be
identified by the use of forward-looking terminology such as &#8220;may,&#8221; &#8220;will,&#8221;
&#8220;expect,&#8221; &#8220;continue,&#8221; &#8220;remains,&#8221; &#8220;intend,&#8221; &#8220;aim,&#8221; &#8220;towards,&#8221; &#8220;should,&#8221;
&#8220;prospects,&#8221; &#8220;could,&#8221; &#8220;future,&#8221; &#8220;potential,&#8221; &#8220;believes,&#8221; &#8220;plans,&#8221; &#8220;likely,&#8221;
&#8220;anticipate,&#8221; &#8220;position,&#8221; &#8220;probable,&#8221; &#8220;committed,&#8221; &#8220;achieve,&#8221; and &#8220;focused,&#8221; or
the negative thereof or other variations thereon or comparable terminology,
constitute &#8220;forward-looking statements&#8221; within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the Securities Exchange
Act of 1934, as amended, and are subject to the safe harbors created thereby.
These statements should be considered as subject to the many risks and
uncertainties that exist in the Company&#8217;s operations and business environment.
Such risks and uncertainties could cause actual results to differ materially
from those projected. These uncertainties include, but are not limited to,
economic conditions, the Company&#8217;s stage of development, the Company&#8217;s ability
to develop a product, the Company&#8217;s ability to gain FDA approval of its
products, market demand and pricing, competitive and cost factors, and other
risk factors as for fully described in the Company&#8217;s filings made with the
SEC.</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #17365d">9700 Great Seneca Highway, Rockville,
MD&#160;&#160;2085</font><font style="DISPLAY: inline; COLOR: #17365d">0</font></font></div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #17365d">301-366-4841&#160;&#160;Fax
301-560-6634</font></font></div>
                </div>
                <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
                <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                  <div id="FTR">
                    <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
                  </div>
                  <div id="PN">
                    <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
                    <div style="WIDTH: 100%; TEXT-ALIGN: center">
                      <hr style="COLOR: black" noshade size="2">
                    </div>
                  </div>
                  <div id="HDR">
                    <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
                  </div>
                </div>
                <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
              </div>
            </div>
          </div>
        </div>
      </div>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>neuralstemlogo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 neuralstemlogo.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#`!`+#`X,"A`.#0X2$1`3&"@:&!86
M&#$C)1TH.C,]/#DS.#=`2%Q.0$1713<X4&U15U]B9VAG/DUQ>7!D>%QE9V/_
MVP!#`1$2$A@5&"\:&B]C0CA"8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-C
M8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V/_P``1"`!?`6X#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#T"BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"L/Q+<7$"VPMI71G8CY3
MC/2MRN?\5.$%HQ&0&;/TQ4RV-J"O41DI?W?"M>3LQZ8EQG]/\*8]]J(<!;N<
MANGS$?GZ8J)X#*%D!;&`N54D$`8R/?CH:1YE\W&>,ODCD#<,5E=GI*,>B_`M
M+>W9R/MURQ[$-U^@)R:A;4-0$@7[;*0>C;S@CUJ-H#*Z,=PR!G"D].X[4UY%
M,H&1@!@6ZC)S_C1<%&/;\"XE[=D<WUR3[-R?H"<FMOPY-/+'<">=IBK#:Q.>
M,5S;6[-.'*EE.&8`'\><8Q[UT/A9]\5QR#AAR._%5%ZF%>,?9MHW:***U/."
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"N>\5H9%M5'=FY].!70US_BIP
MBVI/(RX/T(Q4RV-L/_$5CGEABX#-ACT!.#C\L?AFHS"?,V9&,9R>.*G:%)&5
MBW&`"05P<?CQ37E1KCEOE*E2P'<Y.?ID_E6)ZJ;Z`D*LNT-R>0K2!2??!&/P
MS43PE90F1@\ACQQ4S1(S!\EBW)`QM)^N>/RIID5IE4D8"E=QZ9.>?ID_E18$
MWT%2#<-H+GOC(!_!<\UT/A1=D-RN<C>,'U&*P7C'V@S*'Z[@N,\_7ICWK?\`
M"O\`JKD`@X91D=^*J.YSXAWILWJ***V/,"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"N>\6(72V`..6)/H,"NAKG_`!4^Q;8D9!+`_0BIEL;8>_M%8YX)
M$&V$#.>Y(/\`A3/*`EP6^3&[=[?YXJ0B)W\PN#C\,^Y'7^=,\U6?'*IC;GOU
MSG\ZQ/53?0>$B:3R]L:'./O'=^?2HC"PDV'TSD>E2O'&SF0%2"<D;QC\\YQ^
M&:1)E^TY;[IP,GV(/ZD?K0";Z!Y4+$J'(;MS_P#6_K71>%%*0W*D@_..1WXK
MGC"L3;@Q/'!8``>_7G\*Z'PH0T-R1TW*!^55'<Y\0_W;-^BBBMCS`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HIJLK#*D$>U.H`**:S!
M1EB`/>A75_NL#CT-`#J*9YL?]]?SI/.C_P">B_F*`N244W<-N[(QZT@EC)P'
M4GZT`/HI,@#)IHE1CA74GT!H`?149EC!P74'ZTHE0G`=2?8T!<?129I:`"BB
MFNZQJ6<A5'4DX`H`=12`YI:`"J]S9V]V%%Q$L@7IGM4K2(IPSJ#[FE5@PRI!
M'J*`3ML4O[&T_P#Y]8_UH_L;3_\`GU3]:O4C,%&6.`.YI617/+N4O[&T[_GU
M3]:/[&T[_GU3]:M1W,,I(CE1R.RL#3RP`R2`/4T60>TEW*7]BZ=_SZQ_K5BV
MM(+0,+>,1ACD@=Z?YT?_`#T7\Q1YL?\`ST7\Q183FWNR2BF>;&2`'4D^]#2(
MI^9@/J:8A]%1^='_`,]%_.G*ZMG:P./0T!<=13/,3=MW#=Z9IU`"T4E(SJGW
MB!]30`ZBD!!&1R*6@`HIK,J#+$`>](LB-]U@?H:`'T4P2(QPK`D>AIU`"T4F
M:8)8R<!U)]C0!)129J.2XBB_UDB)_O,!0!+144=Q#*<1RH_^ZP-2`YH`Q'(T
M6_W#)M9\DJ/^69&.?IS6S&ZR(KH0RL,@CO5:XC66]CCD&5:&0$>V4JE#(VD7
M2VLF6M9#^Z<_PD]C_G_ZU;^IDGROR-:2-9$*NH93U!&1572H(X;)?+0+G.2.
MIY/6KF<BJ^G_`/'G'^/\S2Z%]3/NH8QK]G^[7YE;=QUX-:,MG;RH5>",@_[(
MK/U%W36[-HXS(P5L*"!G@^M66N[P*2-.?./^>J_XTWT(5KNY9A@6&W6`<HHV
M\^E9FE0QKJFH8C4;&7;QTZ]*TK.1YK6.21=KL,E?2J.F?\A34O\`>7^M"V8W
M:\34QD8/2L[38(EFNV6-`PG*@@=!@<5I51T__67G_7PW\A2Z%/=%:[AC_MVR
M^1?F#[N.O!ZU<N-/M9U(:%`>S*,,/H:J7[B/6K%V#$!7^ZI8]#V%2S:K&'\F
M*&:28C*H4*_S[4]=+$+E5[C=)GF\V>TN&WO`1ASU8'IFM.L_3+22%I;BX(,\
MYRP'11V%:%)VOH7"]M1*S=5#7>VQB.&=2[GT`Z?F<?K6D:S+2]M6EGG>XA5G
M;:H9P/E'`_/D_C0NXI6>A/I5P+BQ1CD.OR.#ZBKE8EE/%!K,D,4B217'S`HP
M(5N3C^?Z5MBB2LP@[HR]9AC9[1FC4EKE%)(Z@]JTU144*H``[`5GZOULO^OI
M/ZUHT/9`OB85G:@4>]L[>;!BD+$J>C$`8!_.M&JU_91WUOY;DJ0<JPZ@T+<<
MDVM!+FQAN8?+90I`^5E'*_2G3VB7%NL,N608)&<9Q5&*]GL)%@U`;HSPDXZ'
MZ_Y_QK6!S0[H2LR%+2!%"K#&`.P450TR&)KJ_!C0@38&1TK5K-TK_C[U#_KM
M0MF$DKHL3Z=;S,C&,(Z$,K(,$8J+68T;3IF95)5>"1TK0JEK'_(+N/\`=H6Z
M"25F.M;>(VD),2$E%_A'I3H+.&WFDDA0)Y@`*J,#C/\`C5:VNKH6T0%@[`(,
M'S%YX^M3VMQ--/(DUN80H4C+`YSGT^E#N":T*NLP!(!>1JHF@8-G'4>E:%O.
MEQ`DL?W6&14.HJ'M@C`$/(BD>HW#/Z9JGI):TNKBP;E4.^,G^Z?\_P`Z>\17
MM/U-:LF:>.ZUR*V90Z1*>HR-W7]!6E<3""!Y&Z*I-9$5NUMJ.GESF242&3ZX
MR?Y_I1$)O8VE4*``,`=`*=24M2:$%Y&DEK('56`4G!&>U4]`C0:7$X50S;LG
M')Y-7KG_`(]I?]P_RJGH/_((@_X%_P"A&J^R9OXUZ$&JVYM)([VT4+-N"LH'
MW\U?LKR.\MQ+'D=B#U!]*CU/[EO_`-?$?\ZJ7<,FFW#7UL-T3?ZZ(?\`H0HW
M5A?"VUL:]4;:WA74KEEB0$!,$*..#5N*5)HEDC8,K#((J"#_`)"%U]$_D:1;
MZ$%[=R/-]BM#B<C+OVC'K]:FMM.@MSN"[Y#R9'^9B?7-5=%7?)>SG[[3E3]!
M_P#KK6IO304?>]YE6ZL(+M2)(QN[..&!^M.LK<VMI'"6#%!C([U8HJ;E65[E
M5_\`D)0_]<I/YI3[JVCNH&BE7<I_3WJI(][]N61;(M&BL@/F*,Y(YZ^U:/UI
M["6MS*T^YFM[@V%X<L!^ZD/\8J[I_P#QYQ_C_,TW4+,7EOLR5=3N1AV-.T^.
M2&RBCE&)`/FYSS3=FKB2:=BG=_\`(P6/^ZW\C6IBLBX2]?5(;E;-BD(8?ZQ?
MFR"/6K9NKS'&GOG_`*ZK_C0UL*+LV7.G%9>F?\A34O\`>7^M6[(W3J[W:"-B
MWRH"#M7ZU!/;SP7QN[6,2&0;9(RP&?0CWH75#>MF:%4M.Y>\_P"OAOY"EEGN
MV7;#9L'/\4KJ%'OP2:EM+86T`CR6;JS'^(GJ:0]V4[O_`)#MA_NO_(T_5+5I
M%%S;C%S#RI'<>E0W27CZG!<)9DI#N'^L7YLY&>M:B%FC4LNUB,E<YQ[4WI8E
M*]TR"PO$O(!(G##AE/535FLVZT^5;C[58,J3'[ZM]U_K[U-!->R,HEM!$H4E
MCO!R?08I6[#3>S%U)G-MY41_>3,(Q[9ZG\LU*EK`B!1$F%&!E15'-\]^DSV1
M$2*0!YBY!/?K6I0]`6KN9FKVRI;"XA15D@8."H`SZC_/I5^WF6>!)4/RN,BB
MX!,#@1F3(QL!QFLO2([^SB$$UJ2F[A@Z_*#U[_C3W0MI$^K];+_KZ3^M:-9F
MI+=S2PK%:EEBF63=O4;L=L9]ZG^U7G_0/?\`[^I_C1;1`G:3+F:0,#T(/TJC
M&U]->(9(/(MU!)&\$L?PI%M[JTN99HOW\<K9,7W2ON"3BE8KF\BY<01W$+1R
MJ&1AR#5/1)'?3U#G.PE`?8=*?-->R)L@M3&S<;Y67"^^`3FK%K`MM;QQ+T08
MSZGN:.@MY7):S=*_X^]0_P"NU:$K,L;,B%V'100,_G6;IZWD-U.TEH52>3=N
M\Q3M_6FMF$OB1JU2UC_D%W'^[5RJ.JK<2VSP06YDWKC=N``_.E'<<_A99M/^
M/2'_`*YK_*I<=ZH0SWD4,<9T]R54#/FIV'UI5FOY;F-3:^3#G+L75B>.G'O0
MT)2'WQ&^U7^],/T!/]*JZR&MS!?1`[HFPV.ZG_/ZT^[^V-?0O':%XX2QSYBC
M=D8]:ORQ+-$T;C*L,$4+2PFN:Z*5S(+N:V@C;<C_`+UR/[HZ?F:;J>$N]/<\
M8EVY^M+I%@]G"_G',A;`/^R.G^/XTW54NYGA6WMMXBD63<7`!QVZTUO83ORW
M>YIBEJ*!Y'C#2Q&)O[I(/\JEJ34BN?\`CVE_W#_*J>@_\@B#_@7_`*$:LWIE
M%NRPPF5FRN`P&..O-5M'CN+>T6WG@,>S/S;@0<DGL:K[)#^-$FI_<M_^OB/^
M=6RH8$$9!ZBJ6IK<N(EM[<R;9%<G<!T/3FK<+.\0:2,QL>JD@X_*ET&OB9DE
M3H]WN4M]AD/S#&?+;_"KULP:^N2"""J=/H:L31)-&T<BAE88(-4M+L7L9)U)
M+1L1Y9)[<\4[W1-FFDMB#3G^RZE=6DAQO;S(\]\_Y_2M>JUY9K<JI#%)4.4D
M'534<,M]%\D]MYN.DD3+\WU!(Q2>NHU[NA=HJG+/>,-L-FP)'WI74`?D32V4
65W`5CF=9$VDM)_$7+9_+!HL.^I__V3\_
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
